Variability of Pentacam-derived Back Elevation Measurements in Keratoconus and Cross-linked Corneas
|ClinicalTrials.gov Identifier: NCT01471873|
Recruitment Status : Completed
First Posted : November 16, 2011
Last Update Posted : January 18, 2017
|Condition or disease||Intervention/treatment|
|Keratoconus||Procedure: Corneal Collagen Cross-linking (CXL)|
The Pentacam Classic (Oculus Optikgerate GmbH, Heidelberg, Germany, software version 1.14r04) was used for the sake of the study.Two study groups were formed: 1) Keratoconus group (KC) included patients with progressive keratoconus and 2) Collagen-Cross-linking group (CXL) included keratoconus patients that had been treated with uneventful CXL at least on year prior to their enrollment in the study.
Three consecutive scans were obtained by two experienced operators. The same procedure was repeated within two weeks for the assessment of intersession variability. In all cases acceptable maps had at least 10.0mm of corneal coverage.All back elevation points were codified in order to facilitate statistical processing of data. Further to single point analysis, three additional parameters were evaluated: a) zone 4 parameter (z4) which derived by the analysis of all points at the central 4.0mm diameter zone, b) zone 8 parameter (z8) which derived by the analysis of all points at the central 8.0mm diameter zone, and, c) highest elevation point parameter (HEP), which derived by the analysis of the highest elevation points for all participants. Reproducibility of measurements was evaluated by means of intraclass correlation coefficients (ICC). Three different ICC types were calculated: a) intrasession ICC for both operators (ICC1 & ICC2), b) interobserver ICC, and, c) intersession ICC. Moreover, Bland-Altman plots were used to evaluate the level of agreement between the two operators.
|Study Type :||Observational|
|Actual Enrollment :||67 participants|
|Observational Model:||Case Control|
|Official Title:||Variability of Pentacam-derived Back Elevation Measurements in Keratoconus and Cross-linked Corneas|
|Study Start Date :||March 2011|
|Actual Primary Completion Date :||September 2011|
|Actual Study Completion Date :||November 2011|
Keratoconus Group (KG)
Keratoconus group (KG) included patients with progressive keratoconus.
Collagen-Cross-linking group (CXLG)
Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
Procedure: Corneal Collagen Cross-linking (CXL)
The same surgical procedure was applied to all CXLG patients that included:
Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
- Variability of posterior corneal surface elevation measurements within and between sessions and within and between observers. [ Time Frame: 2 weeks ]The Pentacam Classic (Oculus Optikgerate GmbH, Heidelberg, Germany, software version 1.14r04) was used for the sake of the study. Three consecutive scans were obtained by two experienced operators for the assessment of intrasession and interobserver variability. The same procedure was repeated within two weeks for the assessment of intersession variability.Bland-Altman plots were used to evaluate agreement between the 2 operators. The reproducibility of all measurements was evaluated by means of the intraclass correlation coefficient(ICC).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01471873
|Eye Institute of Thrace (EIT)|
|Alexandroupolis, Thrace, Greece, 67100|